Status:

UNKNOWN

Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease.

Lead Sponsor:

Samsung Medical Center

Conditions:

Hemodialysis Access Failure

Eligibility:

All Genders

20-80 years

Phase:

NA

Brief Summary

This prospective, multicenter, non-randomized, single-arm Clinical trial aims to evaluate the safety and effectiveness of the use of paclitaxel-coated arteriovenous graft (AVG) on the inner wall of eP...

Detailed Description

1. Evaluation of safety Primary outcome: all adverse events occurring in the subject 2. Evaluation of effectiveness Primary outcome: AV graft primary patency Secondary outcome: AV graft secondary pate...

Eligibility Criteria

Inclusion

  • Adult male or female between the ages of 20 and 80
  • Patients currently undergoing or scheduled for hemodialysis due to end-stage kidney disease.
  • Patients who decided to receive AVG procedure in forearm due to inability to perform autologous arteriovenous fistula (AVF)
  • Patients with a high risk of stenosis (neointimal hyperplasia) or thrombosis when artificial blood vessels were implanted

Exclusion

  • Pregnant or lactating women
  • Patients who are currently diagnosed with malignant tumors and are receiving chemotherapy or radiotherapy
  • Patients with life expectancy less than 12 months
  • Patients expected to receive a kidney transplant during the trial
  • Patients with current or suspected infection
  • Acute psychiatric problems require treatment
  • Patients who have inserted a catheter into an artery or vein in their upper limb for AVG procedure within the last 30 days
  • Patients with coagulation disorder, platelet count \<50,000 / Ul
  • Patients with a neutrophil count of less than 1,500 cells / mm3
  • Patients judged to be unable to insert grafts by the operator

Key Trial Info

Start Date :

November 13 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2023

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT04285073

Start Date

November 13 2018

End Date

December 31 2023

Last Update

February 26 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Samsung Medical Center

Seoul, South Korea, 135-710